Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.34 |
| ▸ | BRS3 | P32247 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500754 | 0.92 | PTPN1 (0.37) | LTB4R2BDKRB1BRS3SLC6A3SLC6A4 | |
| SCHEMBL5499130 | 0.89 | VDR (0.33) | ALDH1A1HPGD | |
| SCHEMBL5500080 | 0.89 | PTPN1 (0.32) | PTPN2PTPN1 | |
| SCHEMBL5500308 | 0.88 | FAAH (0.33) | FAAHPTPN2PTPN1 | |
| SCHEMBL5503152 | 0.87 | PTPN1 (0.35) | BDKRB1BRS3FAAHPDK2ALDH1A1 | |
| SCHEMBL5521865 | 0.87 | PTPN1 (0.35) | LTB4R2BDKRB1BRS3SLC6A3SLC6A4 | |
| SCHEMBL5503199 | 0.84 | PTPN1 (0.34) | PTPN2PTPN1 | |
| SCHEMBL5503912 | 0.84 | PTPN1 (0.38) | LTB4R2BRS3RAB9APTPN2PTPN1 | |
| SCHEMBL5500755 | 0.83 | SLC6A3 (0.34) | LTB4R2BDKRB1BRS3SLC6A3SLC6A4 | |
| SCHEMBL5500052 | 0.83 | PTPN1 (0.37) | FAAHKDM4EPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | PTPRO, PTPRG, PTPN1 | LTB4R2 2923/4885BDKRB1 3825/4885BRS3 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.